La rivoluzione copernicana nella terapia dell'artrite reumatoide: il contributo degli anti-TNFalpha.

Translated title of the contribution: Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs

S. Bombardieri, G. Ferraccioli, C. Ferri, M. Galeazzi, G. Lapadula, M. Matucci Cerinic, C. Montecucco, G. Triolo, F. Trotta, G. Valentini

Research output: Contribution to journalArticlepeer-review


TNFalpha has a key role in cell recruitment, proliferation and death, expression of adhesion molecules and immune responses. In RA, TNFalpha is involved in matrix degradation and osteoclastogenesis. TNFalpha inhibitors are either soluble receptors (etanercept) or monoclonal antibodies (infliximab and adalimumab; golimumab and certolizumab are in development). TNFalpha antagonists, alone or in combination with methotrexate, reduce bone erosions and thinning of cartilage, but they differ as regards ligand binding, pharmacokinetics, pharmacodynamics, and clinical indications. Etanercept is the only TNFalpha antagonist that also neutralises LFT-alpha. Infliximab and adalimumab are more immunogenic. Cytotoxicity and cellular lysis are also higher with infliximab and adalimumab. Etanercept slows progression of joint damage in recently diagnosed RA when given alone, but much more when given with methotrexate; anti-TNF monoclonal antibodies also were shown to slow progression alone and in combination with methotrexate. Patients with early and long-standing RA treated with etanercept have now shown improvement in ACR scores, inflammation and disability for up to 9 years. Outcomes with infliximab and adalimumab are similar to those with etanercept, but only in combination with methotrexate. As a result of neutralizing antibodies, increasing doses of anti-TNFalpha antibodies may be required to maintain clinical response. As regards side effects, opportunistic infections seem more frequent with monoclonal antibodies. TNFalpha antagonists produce more QALYs than traditional DMARDs, counteracting higher costs. The efficacy, safety, and quality of life benefits of TNFalpha antagonists suggest using them possibly earlier than today, even in clinically moderate RA. Thanks to its overall profile, etanercept might be considered as one of the first-choices in TNFalpha antagonism in RA management.

Translated title of the contributionCopernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs
Original languageItalian
Pages (from-to)1-23
Number of pages23
Volume61 Suppl 1
Publication statusPublished - Apr 2009

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs'. Together they form a unique fingerprint.

Cite this